loading
Schlusskurs vom Vortag:
$0.8074
Offen:
$0.8043
24-Stunden-Volumen:
2.81M
Relative Volume:
0.90
Marktkapitalisierung:
$280.26M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.1607
EPS:
-0.68
Netto-Cashflow:
$-162.37M
1W Leistung:
-25.46%
1M Leistung:
-59.48%
6M Leistung:
-52.69%
1J Leistung:
-26.84%
1-Tages-Spanne:
Value
$0.7633
$0.8346
1-Wochen-Bereich:
Value
$0.7633
$1.08
52-Wochen-Spanne:
Value
$0.7633
$3.73

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Firmenname
Lexicon Pharmaceuticals Inc
Name
Telefon
(281) 863-3000
Name
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Mitarbeiter
285
Name
Twitter
@LexPharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
LXRX's Discussions on Twitter

Vergleichen Sie LXRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
LXRX 0.7901 280.26M 1.21M -177.12M -162.37M -0.68
VRTX 449.64 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.66 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.18 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.13 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.50 24.89B 3.30B -501.07M 1.03B 11.54

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-03-07 Eingeleitet Jefferies Hold
2022-08-12 Eingeleitet Piper Sandler Overweight
2021-01-29 Hochstufung JP Morgan Underweight → Neutral
2021-01-29 Herabstufung Wedbush Outperform → Neutral
2020-12-08 Hochstufung Citigroup Neutral → Buy
2020-11-18 Hochstufung Gabelli & Co Hold → Buy
2019-12-11 Herabstufung Gabelli & Co Buy → Hold
2019-11-08 Herabstufung Citigroup Buy → Neutral
2019-09-11 Hochstufung Gabelli & Co Hold → Buy
2019-07-29 Herabstufung Stifel Buy → Hold
2019-03-25 Hochstufung Gabelli & Co Sell → Hold
2018-07-31 Bestätigt Stifel Buy
2018-02-23 Herabstufung Needham Buy → Hold
2018-02-14 Herabstufung JP Morgan Neutral → Underweight
2017-03-01 Bestätigt H.C. Wainwright Buy
2017-03-01 Bestätigt Wedbush Outperform
2016-10-07 Eingeleitet H.C. Wainwright Buy
2016-08-05 Bestätigt Wedbush Outperform
2016-08-02 Eingeleitet Citigroup Buy
2016-03-02 Bestätigt Wedbush Outperform
2015-11-09 Bestätigt Wedbush Outperform
2015-09-28 Hochstufung Gabelli & Co Sell → Hold
2015-09-18 Herabstufung Gabelli & Co Hold → Sell
2015-08-10 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

pulisher
01:01 AM

Lexicon Appoints Ivan Cheung to Board of Directors - citybiz

01:01 AM
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com South Africa

Nov 20, 2024
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com

Nov 20, 2024
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com

Nov 20, 2024
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com

Nov 20, 2024
pulisher
Nov 18, 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlig - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Lexicon: Q3 Earnings Snapshot - The Washington Post

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of Lexicon Pharmaceuticals Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

LXRXLexicon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings: EPS of -$0. - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 11, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Previ - GuruFocus.com

Nov 11, 2024
pulisher
Nov 11, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance

Nov 11, 2024
pulisher
Nov 06, 2024

Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Tuesday - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Lexicon Pharmaceuticals CEO to Present at Jefferies London Healthcare Conference | LXRX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals - Benzinga

Nov 05, 2024
pulisher
Nov 05, 2024

HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 - The Manila Times

Nov 05, 2024
pulisher
Nov 04, 2024

Pharma Stock Has Significant Upside Potential, Analyst Says - Streetwise Reports

Nov 04, 2024
pulisher
Nov 04, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss - StockTitan

Nov 04, 2024
pulisher
Nov 03, 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Hold” Rating at Needham & Company LLC - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread - The Pharma Letter

Nov 01, 2024
pulisher
Nov 01, 2024

Lexicon stock in selloff on FDA AdCom rebuke (LXRX:NASDAQ) - Seeking Alpha

Nov 01, 2024
pulisher
Nov 01, 2024

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote - MarketWatch

Nov 01, 2024
pulisher
Nov 01, 2024

Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners - StreetInsider.com

Nov 01, 2024
pulisher
Nov 01, 2024

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - The Manila Times

Nov 01, 2024
pulisher
Oct 31, 2024

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters.com

Oct 31, 2024
pulisher
Oct 31, 2024

FDA advisers vote against Lexicon Pharma’s add-on drug for type 1 diabetes - PharmaLive

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication - Citeline News & Insights

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista - MarketWatch

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update - MarketWatch

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista — Update - Morningstar

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista - Morningstar

Oct 31, 2024

Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):